Exploration of the Efficacy and Mechanisms of Lymphaticovenous Anastomosis in the Treatment of Alzheimer's Disease

Launched by LUO XINXIN · Nov 25, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a surgical procedure called Lymphaticovenous Anastomosis to see if it can help improve symptoms in patients with Alzheimer's disease. The main goal is to find out if this procedure can enhance thinking skills, daily activities, mood, and sleep in patients aged 18 to 80 who have been diagnosed with Alzheimer's for at least a year. Additionally, the researchers want to observe any changes in blood tests and brain scans after the surgery.

To participate in this study, potential participants should have a confirmed diagnosis of Alzheimer's disease and meet specific health criteria. For example, they should be between 18 and 80 years old, have a certain level of cognitive impairment, and show specific changes in brain scans. However, the trial will not accept individuals with certain serious health conditions or mental health disorders. If someone decides to join the study, they will need to give their consent and can expect to undergo the surgery along with follow-up assessments to evaluate its effects. This trial is currently not recruiting participants, but it aims to gather valuable information that could lead to better treatment options for Alzheimer's disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. At least two deputy chief physicians or above, diagnosed with Alzheimer's dementia according to the DSM-5 diagnostic criteria;
• • 2. Age between 18-80 years old;
• • 3. The course of the disease is at least 1 year;
• • 4. MMSE score ≤ 24 points; MoCA score \< 26
• • 5. Brain MRI shows hippocampal atrophy;
• • 6. Patients and their families agree to participate in this project for surgical treatment and sign an informed consent form.
• Exclusion Criteria:
• • 1. Individuals with contraindications for Lymphaticovenous Anastomosis; those allergic to anesthetics and contrast agents (indocyanine green);
• • 2. Those unable to cooperate with cranial magnetic resonance imaging and scale testing;
• • 3. Patients simultaneously suffering from schizophrenia, depression, bipolar disorder;
• • 4. Patients with severe somatic diseases (such as cardiovascular, liver, kidney, gastrointestinal, etc.), infectious diseases, and immune system disorders;
• • 5. Individuals with serious neurological diseases (such as epilepsy, cerebrovascular diseases, etc.), other types of dementia, mental retardation;
• • 6. Pregnant or lactating women.